Recombinant Human VISTA/B7-H5/PD-1H Fc Avi-tag Protein, CF

When Recombinant Human VSIG3 Fc Chimera (Catalog # 9229-VS) is coated at 5 μg/mL, Biotinylated Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Avi-tag (Catalog # AVI7126) binds with an ED50 of 0.5-3 μg/mL.

2 μg/lane of Biotinylated Recombinant Human VISTA/B7-H5/PD-1HFc Chimera Avi-tag (Catalog # AVI7126) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 64-75 kDa and130-150 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VISTA/B7-H5/PD-1H Fc Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human VSIG3 Fc Chimera (Catalog # 9229-VS) is immobilized at 5 µg/mL (100 µL/well), Biotinylated Recombinant Human VISTA/B7-H5/PD-1H Fc Chimera Avi-tag (Catalog # AVI7126) binds with an ED₅₀ of 0.5-3 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human VISTA/B7-H5/PD-1H protein
  

  Human VISTA/B7-H5/PD-1H (Phe33-Ala194) Accession # AAH20568	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: AAH20568
• N-terminal Sequence: Phe33
• Structure / Form: Disulfide-linked homodimer, biotinylated protein via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 47 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 64-75 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VISTA/B7-H5/PD-1H Fc Avi-tag Protein, CF

• 4632428N05Rik
• B7H5
• B7-H5
• C10orf54
• chromosome 10 open reading frame 54
• Dies1
• Gi24
• PD1H
• PD-1H
• platelet receptor Gi24
• PP2135
• SISP1
• stress induced secreted protein 1
• VISTA
• VSIR

Background

Platelet receptor Gi24, also known as Dies1, VISTA, SISP1 and B7‑H5, is a 55‑65 kDa transmembrane glycoprotein with homology to B7‑like immune co‑stimulatory molecules (1, 2). Mature human Gi24 contains a 162 amino acid (aa) extracellular domain (ECD) with one V‑type Ig‑like domain, a 21 aa transmembrane segment, and a 96 aa cytoplasmic domain. Within the ECD, human Gi24 shares 70% and 67% aa sequence identity with mouse and rat Gi24, respectively (3). The 30 kDa ECD can be shed by MT1‑MMP, with a 25‑30 kDa fragment remaining in the membrane (3). Gi24 promotes both MT1‑MMP expression and the MT1‑MMP mediated activation of MMP‑2 (3). Gi24 supports the differentiation of embryonic stem cells (ESC) and enhances BMP‑4 induced signaling in ESC, but is also down‑regulated following BMP‑4 exposure (4, 5). It binds to BMP‑4 directly, and also associates with the type I BMP receptor Activin RIB/ALK‑4 (4, 5). Gi24 is expressed on the surface of naïve CD4⁺ T cells and regulatory T cells (6). It is up‑regulated in vivo on activated monocytes and dendritic cells (5). Gi24 inhibits CD4⁺ and CD8⁺ T cell proliferation, and their production of IL‑2 and IFN‑ gamma (6). Its expression on tumor cells attenuates the anti‑tumor immune response and enables more rapid tumor progression (6). In contrast, Gi24 limits disease progression in the autoimmune disease model EAE (6).

1. Flajnik, M.F. et al. (2012) Immunogenetics 64:571.
2. Wilcox, R.A. et al. (2012) Eur. J. Haematol. 88:465.
3. Sakr, M.A. et al. (2010) Cancer Sci. 101:2368.
4. Aloia, L. et al. (2010) J. Biol. Chem. 285:7776.
5. Parisi, S. et al. (2012) FASEB J. 26:3957.
6. Wang, L. et al. (2011) J. Exp. Med. 208:577.

Bioinformatics

• Uniprot:
  • AAH20568()